News | October 30, 2022
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
The girl child anthem will portray a celebration of a girl child.
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Xi Experience centre is aimed at familiarizing and bringing awareness about robotic-assisted surgery among the surgical fraternity in the country
_256_384.png)
Amongst the first pharmaceutical companies in India and Asia to be recognised for adopting advanced fourth industrial revolution technologies to digitally transform operations
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Cumulatively, almost 75% of the health centres in the country have been electrified with a cumulative solar capacity of 3.5 MW
Subscribe To Our Newsletter & Stay Updated
